In summary, the present study demonstrated that NGR1 treatment inhibited the production of pro-inflammatory cytokines and NO in LPS treated AW264.7 cells, which might be mediated by inhibiting the activation of NF-κB/NLRP3 inflammation signaling pathway and might therefore relieve atopic dermatitis. This evidence concerns the gene NFKB1 and atopic eczema.